Dacomitinib (BioDeep_00000177925)
human metabolite blood metabolite
代谢物信息卡片
N-{4-[(3-chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enimidate
化学式: C24H25ClFN5O2 (469.1680712)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1=C(NC(=O)C=CCN2CCCCC2)C=C2C(NC3=CC(Cl)=C(F)C=C3)=NC=NC2=C1
InChI: InChI=1S/C24H25ClFN5O2/c1-33-22-14-20-17(24(28-15-27-20)29-16-7-8-19(26)18(25)12-16)13-21(22)30-23(32)6-5-11-31-9-3-2-4-10-31/h5-8,12-15H,2-4,9-11H2,1H3,(H,30,32)(H,27,28,29)
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
1 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Wen-Chien Cheng, Chi-Chien Lin, Wei-Chih Liao, Yu-Chao Lin, Chia-Hung Chen, Hung-Jen Chen, Chih-Yen Tu, Te-Chun Hsia. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study.
BMC cancer.
2024 Feb; 24(1):228. doi:
10.1186/s12885-024-11956-w. [PMID: 38373960] - Xiaojia Yang, Jinfang Li, Taihui Zhang, Qinping Xia, Wei Zhang, Yike Cui, Wen He. Bioequivalence study of dacomitinib and Vizimpro® in healthy Chinese volunteers under fasting and fed conditions: A randomized, open-label, single-dose, crossover trial.
Clinical and translational science.
2023 12; 16(12):2591-2603. doi:
10.1111/cts.13653. [PMID: 37786330] - Fei Qiao, Qinlei Chen, Weiting Lu, Nanyuan Fang. Plasma exchange treats severe intrahepatic cholestasis caused by dacomitinib: A case report.
Medicine.
2022 Jul; 101(27):e29629. doi:
10.1097/md.0000000000029629. [PMID: 35801736] - Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Ouki Kuniyoshi, Itaru Sato, Naoki Nakaya, Hideo Nakajima, Motonori Kimura, Jun Hakamata, Naoya Suehiro, Hideo Nakada, Shinnosuke Ikemura, Aya Jibiki, Hitoshi Kawazoe, Hiroshi Muramatsu, Sayo Suzuki, Tomonori Nakamura. Development and validation of a new liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of afatinib, dacomitinib, osimertinib, and the active metabolites of osimertinib in human serum.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2022 May; 1199(?):123245. doi:
10.1016/j.jchromb.2022.123245. [PMID: 35436724] - Joseph Piscitelli, Joseph Chen, Robert R LaBadie, Joanne Salageanu, Chin-Hee Chung, Weiwei Tan. The Effect of Hepatic Impairment on the Pharmacokinetics of Dacomitinib.
Clinical drug investigation.
2022 Mar; 42(3):221-235. doi:
10.1007/s40261-022-01125-x. [PMID: 35195881] - Weiping Ji, Jiquan Shen, Bo Wang, Feifei Chen, Deru Meng, Shuanghu Wang, Dapeng Dai, Yunfang Zhou, Changxiong Wang, Quan Zhou. Effects of dacomitinib on the pharmacokinetics of poziotinib in vivo and in vitro.
Pharmaceutical biology.
2021 Dec; 59(1):457-464. doi:
10.1080/13880209.2021.1914114. [PMID: 33899675] - Yuji Mukai, Azusa Wakamoto, Tae Hatsuyama, Tatsunari Yoshida, Hideki Sato, Akihisa Fujita, Nobuo Inotsume, Takaki Toda. An Liquid Chromatography-Tandem Mass Spectrometry Method for the Simultaneous Determination of Afatinib, Alectinib, Ceritinib, Crizotinib, Dacomitinib, Erlotinib, Gefitinib, and Osimertinib in Human Serum.
Therapeutic drug monitoring.
2021 12; 43(6):772-779. doi:
10.1097/ftd.0000000000000895. [PMID: 33871406] - Xiangling Feng, Yufeng Ding, Peng Zhang, Qiang Fu, Li Zhang, Heng Zheng. Simultaneous determination of dacomitinib and its major metabolite, O-desmethyl dacomitinib in human plasma by LC-MS/MS and its application to clinical testing in patients with non-small cell lung cancer.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2021 Oct; 1182(?):122940. doi:
10.1016/j.jchromb.2021.122940. [PMID: 34564058] - G D Marijn Veerman, Peter de Bruijn, Anne-Marie C Dingemans, Ron H J Mathijssen, Stijn L W Koolen. To quantify the small-molecule kinase inhibitors ceritinib, dacomitinib, lorlatinib, and nintedanib in human plasma by liquid chromatography/triple-quadrupole mass spectrometry.
Journal of pharmaceutical and biomedical analysis.
2021 Jan; 193(?):113733. doi:
10.1016/j.jpba.2020.113733. [PMID: 33217707] - Ryo Ariyasu, Noriko Yanagitani, Kenichi Tadokoro, Toshikazu Yamaguchi, Ken Uchibori, Satoru Kitazono, Naoya Fujita, Ryohei Katayama, Makoto Nishio. Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms.
Cancer chemotherapy and pharmacology.
2020 10; 86(4):517-525. doi:
10.1007/s00280-020-04136-7. [PMID: 32948919] - Weiwei Tan, Nagdeep Giri, Susan Quinn, Keith Wilner, Kourosh Parivar. Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer.
Investigational new drugs.
2020 06; 38(3):874-884. doi:
10.1007/s10637-019-00887-0. [PMID: 31858327] - J Gao, H-R Li, C Jin, J-H Jiang, J-Y Ding. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
2019 Oct; 21(10):1287-1301. doi:
10.1007/s12094-019-02075-1. [PMID: 30864018] - Jesús Corral, Tony S Mok, Kazuhiko Nakagawa, Rafael Rosell, Ki Hyeong Lee, Maria Rita Migliorino, Adam Pluzanski, Rolf Linke, Geeta Devgan, Weiwei Tan, Susan Quinn, Tao Wang, Yi-Long Wu. Effects of dose modifications on the safety and efficacy of dacomitinib for EGFR mutation-positive non-small-cell lung cancer.
Future oncology (London, England).
2019 Aug; 15(24):2795-2805. doi:
10.2217/fon-2019-0299. [PMID: 31313942] - Xiangjun Qiu, Qianmeng Lin, Zongdi Ning, Xin Qian, Pengbo Li, Lei Ye, Saili Xie. Quantitative bioanalytical assay for the human epidermal growth factor receptor (HER) inhibitor dacomitinib in rat plasma by UPLC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2019 Mar; 166(?):66-70. doi:
10.1016/j.jpba.2018.12.041. [PMID: 30612075] - Xia Chen, Ji Jiang, Nagdeep Giri, Pei Hu. Phase 1 study to investigate the pharmacokinetic properties of dacomitinib in healthy adult Chinese subjects genotyped for CYP2D6.
Xenobiotica; the fate of foreign compounds in biological systems.
2018 May; 48(5):459-466. doi:
10.1080/00498254.2017.1342881. [PMID: 28648122] - Ysabella Z A Van Sebille, Rachel J Gibson, Hannah R Wardill, Imogen A Ball, Dorothy M K Keefe, Joanne M Bowen. Dacomitinib-induced diarrhea: Targeting chloride secretion with crofelemer.
International journal of cancer.
2018 01; 142(2):369-380. doi:
10.1002/ijc.31048. [PMID: 28921512] - Ysabella Z A Van Sebille, Rachel J Gibson, Hannah R Wardill, Kate R Secombe, Imogen A Ball, Dorothy M K Keefe, John W Finnie, Joanne M Bowen. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats.
International journal of cancer.
2017 06; 140(12):2820-2829. doi:
10.1002/ijc.30699. [PMID: 28316082] - Dong-Wan Kim, Edward B Garon, Aminah Jatoi, Dorothy M Keefe, Mario E Lacouture, Stephen Sonis, Diana Gernhardt, Tao Wang, Nagdeep Giri, Jim P Doherty, Sashi Nadanaciva, Joseph O'Connell, Eric Sbar, Byoung Chul Cho. Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).
Lung cancer (Amsterdam, Netherlands).
2017 04; 106(?):76-82. doi:
10.1016/j.lungcan.2017.01.021. [PMID: 28285698] - Ana Ruiz-Garcia, Joanna C Masters, Laure Mendes da Costa, Robert R LaBadie, Yali Liang, Grace Ni, Craig A Ellery, Tanya Boutros, Zelanna Goldberg, Carlo L Bello. Effect of food or proton pump inhibitor treatment on the bioavailability of dacomitinib in healthy volunteers.
Journal of clinical pharmacology.
2016 02; 56(2):223-30. doi:
10.1002/jcph.588. [PMID: 26179237] - Laura Montermini, Brian Meehan, Delphine Garnier, Wan Jin Lee, Tae Hoon Lee, Abhijit Guha, Khalid Al-Nedawi, Janusz Rak. Inhibition of oncogenic epidermal growth factor receptor kinase triggers release of exosome-like extracellular vesicles and impacts their phosphoprotein and DNA content.
The Journal of biological chemistry.
2015 Oct; 290(40):24534-46. doi:
10.1074/jbc.m115.679217. [PMID: 26272609] - Nagdeep Giri, Joanna C Masters, Anna Plotka, Yali Liang, Tanya Boutros, Patricia Pardo, Joseph O'Connell, Carlo Bello. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib.
Investigational new drugs.
2015 08; 33(4):931-41. doi:
10.1007/s10637-015-0256-0. [PMID: 26048096] - Carlo L Bello, Evan Smith, Ana Ruiz-Garcia, Grace Ni, Christine Alvey, Cho-Ming Loi. A phase I, open-label, mass balance study of [(14)C] dacomitinib (PF-00299804) in healthy male volunteers.
Cancer chemotherapy and pharmacology.
2013 Aug; 72(2):379-85. doi:
10.1007/s00280-013-2207-9. [PMID: 23760812] - Carlo L Bello, Robert R LaBadie, Grace Ni, Tanya Boutros, Carol McCormick, M Noella Ndongo. The effect of dacomitinib (PF-00299804) on CYP2D6 activity in healthy volunteers who are extensive or intermediate metabolizers.
Cancer chemotherapy and pharmacology.
2012 Apr; 69(4):991-7. doi:
10.1007/s00280-011-1793-7. [PMID: 22147075]